Go Back   HER2 Support Group Forums > Articles of Interest
Register Gallery FAQ Members List Calendar Search Today's Posts Mark Forums Read

Thread Tools Display Modes
Old 07-22-2003, 06:29 AM   #1
Paul C.
Posts: n/a
This article appears in the the BreastCancerUpdate Journal Vol 5. The article is edited by Mark D Pegram MD
Associate Professor of Medicine David Geffen School of Medicine at UCLA Director Women’s Cancer Program UCLA/Jonsson Comprehensive Cancer Center. Dr. Pegram covers many topics relevant to HER-2 positive breast cancer treatment including:

Early Phase I experience with trastuzumab/cisplatin in metastatic disease

Phase III randomized trial of trastuzumab/paclitaxel with or without carboplatin

Trastuzumab/platinum/taxane regimens

First-line therapy for patients with HER2-positive metastatic disease

BCIRG-006 adjuvant trastuzumab trial

Adjuvant trastuzumab in the nonprotocol setting

Influence of trastuzumab therapy on tumor HER2 status

Trials combining trastuzumab with hormonal therapy

Fulvestrant in clinical practice

Potential synergy between fulvestrant and trastuzumab

Trials combining trastuzumab with biologic agents (i.e. Erlotinib and Bevacizumab)

Treatment options for patients with ER-negative HER2- negative metastatic disease

Transition from hormonal therapy to chemotherapy

Phase III trial comparing capecitabine with or without bevacizumab

ECOG-E-2100: Phase III trial comparing paclitaxel with or without bevacizumab

Use of adjuvant dose-dense chemotherapy schedules

As you know Dr. Dennis Slamon (father of Herceptin/trastuzumab) is based at UCLA. I find the articles written or edited by the doctors at UCLA insightful.

Of course all treatment options should be discussed fully with your doctor.

  Reply With Quote

Thread Tools
Display Modes

Posting Rules
You may not post new threads
You may not post replies
You may not post attachments
You may not edit your posts

BB code is On
Smilies are On
[IMG] code is On
HTML code is On

Forum Jump

All times are GMT -7. The time now is 10:39 PM.

Powered by vBulletin® Version 3.8.7
Copyright ©2000 - 2020, vBulletin Solutions, Inc.
Copyright HER2 Support Group 2007
free webpage hit counter